Miguel Hernandez Pampaloni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Miguel Hernandez Pampaloni has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- David M. Naeger
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
2 shared publications Elias Botvinick
UCSF
2 shared publications- Lorenzo Nardo
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
2 shared publications - Lorenzo Nardo
Department of Radiology, University of California Davis, Sacramento, CA
2 shared publications - Luca Facchetti
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, USA
2 shared publications Robert R. Flavell
2 shared publications
Latest Publications
- 7 June 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (11) , 1288-1291
False positive pharmacologic myocardial perfusion SPECT study in the setting of a left bundle branch block
We herein report a case of a false positive vasodilatory pharmacologic SPECT stress test in the setting of a left bundle branch block (LBBB). While this is more commonly seen with exercise stress testing, it can also occur with pharmacologic stress testing. In our SPECT exam, we illustrate the commonly mistaken septal/anteroseptal perfusion defects in those patients with a LBBB. PET stress testing may be more reliable for patients with LBBB.
- 7 June 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (11) , 1288-1291
False positive pharmacologic myocardial perfusion SPECT study in the setting of a left bundle branch block
We herein report a case of a false positive vasodilatory pharmacologic SPECT stress test in the setting of a left bundle branch block (LBBB). While this is more commonly seen with exercise stress testing, it can also occur with pharmacologic stress testing. In our SPECT exam, we illustrate the commonly mistaken septal/anteroseptal perfusion defects in those patients with a LBBB. PET stress testing may be more reliable for patients with LBBB.
- Open Access
- 22 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2920
Beneficial Effects of Melatonin on Apolipoprotein-E Knockout Mice by Morphological and 18F-FDG PET/CT Assessments
Atherosclerosis represents one of the main risk factors for the development of cardiovascular diseases. Their etiologies have been studied in recent years in order to better define therapeutic targets for intervention and to identify diagnostic methods. Two different subtypes of macrophages, M1 and M2, have been described in physiological conditions. They can also be found in the atherosclerotic process, where they both have opposite roles in disease progression. Perivascular brown adipose tissue is also involved in inflammation and endothelial damage. In this work, we provide insights into the protective role of melatonin in the atherosclerotic process by morphological and 18F-FDG-PET/CT analyses. In particular, we examined the effects of melatonin on pathways that are linked to atherosclerosis development. We showed that melatonin, by suppressing M1 activity, reduced inflammation and directed macrophage polarization toward the M2 macrophage subtype. Moreover, melatonin preserved the activity of perivascular brown adipose tissue. In addition, 18F-FDG uptake is very high in mice treated with melatonin, confirming that other factors may alter 18F-FDG distribution. In conclusion, we showed that melatonin affects inflammatory pathways that have been linked to atherosclerosis, assessed the relationships of the 18F-FDG PET/CT parameters with macrophage markers and the production of their cytokines, which that have been defined by morphological evaluations.
- 22 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2920
Open AccessBeneficial Effects of Melatonin on Apolipoprotein-E Knockout Mice by Morphological and 18F-FDG PET/CT Assessments
Atherosclerosis represents one of the main risk factors for the development of cardiovascular diseases. Their etiologies have been studied in recent years in order to better define therapeutic targets for intervention and to identify diagnostic methods. Two different subtypes of macrophages, M1 and M2, have been described in physiological conditions. They can also be found in the atherosclerotic process, where they both have opposite roles in disease progression. Perivascular brown adipose tissue is also involved in inflammation and endothelial damage. In this work, we provide insights into the protective role of melatonin in the atherosclerotic process by morphological and 18F-FDG-PET/CT analyses. In particular, we examined the effects of melatonin on pathways that are linked to atherosclerosis development. We showed that melatonin, by suppressing M1 activity, reduced inflammation and directed macrophage polarization toward the M2 macrophage subtype. Moreover, melatonin preserved the activity of perivascular brown adipose tissue. In addition, 18F-FDG uptake is very high in mice treated with melatonin, confirming that other factors may alter 18F-FDG distribution. In conclusion, we showed that melatonin affects inflammatory pathways that have been linked to atherosclerosis, assessed the relationships of the 18F-FDG PET/CT parameters with macrophage markers and the production of their cytokines, which that have been defined by morphological evaluations.
- Open Access
- 26 September 2018
- Published by Cureus, Inc. in Cureus
- Vol. 10 (9) , e3364
Delayed Fluorodeoxyglucose Positron Emission Tomography Imaging in the Differentiation of Tumor Recurrence and Radiation Necrosis in Pediatric Central Nervous System Tumors: Case Report and Review of the Literature
Malignant central nervous system (CNS) tumors are often treated with radiation therapy, after which clinical and radiographic sequelae can lead to difficulties differentiating tumor recurrence from treatment effect. Magnetic resonance imaging (MRI) is often unable to distinguish between these two entities. The improved ability to delineate concerning foci could lead to earlier tumor detection with quicker access to new therapies and/or clinical trials; conversely, it could alleviate patient concerns in the case of radiation necrosis as the etiology. The utility of positron emission tomography with computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) has been explored in CNS tumors in the past, as this imaging modality is widely used in oncologic practices. As there are concerns with false positive imaging in the case of cells with a high metabolic uptake due to causes other than malignancy (i.e. infection, inflammation), delayed FDG PET imaging has been proposed as a mechanism to reduce this confusion. Delayed FDG PET imaging has been explored in several adult and pediatric malignancies, including adult CNS tumors, though there are no current publications applying its use in pediatric CNS tumors. We present two cases of pediatric CNS tumors, where delayed FDG PET imaging helped in the early diagnosis of a recurrence through a distinguishing tumor from the treatment effect.
- 26 September 2018
- Published by Cureus, Inc. in Cureus
- Vol. 10 (9) , e3364
Open AccessDelayed Fluorodeoxyglucose Positron Emission Tomography Imaging in the Differentiation of Tumor Recurrence and Radiation Necrosis in Pediatric Central Nervous System Tumors: Case Report and Review of the Literature
Malignant central nervous system (CNS) tumors are often treated with radiation therapy, after which clinical and radiographic sequelae can lead to difficulties differentiating tumor recurrence from treatment effect. Magnetic resonance imaging (MRI) is often unable to distinguish between these two entities. The improved ability to delineate concerning foci could lead to earlier tumor detection with quicker access to new therapies and/or clinical trials; conversely, it could alleviate patient concerns in the case of radiation necrosis as the etiology. The utility of positron emission tomography with computed tomography (PET/CT) imaging with fluorodeoxyglucose (FDG) has been explored in CNS tumors in the past, as this imaging modality is widely used in oncologic practices. As there are concerns with false positive imaging in the case of cells with a high metabolic uptake due to causes other than malignancy (i.e. infection, inflammation), delayed FDG PET imaging has been proposed as a mechanism to reduce this confusion. Delayed FDG PET imaging has been explored in several adult and pediatric malignancies, including adult CNS tumors, though there are no current publications applying its use in pediatric CNS tumors. We present two cases of pediatric CNS tumors, where delayed FDG PET imaging helped in the early diagnosis of a recurrence through a distinguishing tumor from the treatment effect.
- 3 November 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (5) , 1865-1868
Abnormal pulmonary 18F-florbetapir uptake in a patient evaluated for recurrent cardiac amyloidosis following orthotopic heart transplant
- 3 November 2017
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 25 (5) , 1865-1868
Abnormal pulmonary 18F-florbetapir uptake in a patient evaluated for recurrent cardiac amyloidosis following orthotopic heart transplant
- Open Access
- 31 October 2016
- Published by MDPI AG in Biomedicines
- Vol. 4 (4) , 24
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.
- 31 October 2016
- Published by MDPI AG in Biomedicines
- Vol. 4 (4) , 24
Open AccessGlioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11572
Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.
11572 Background: Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed by 18F-FDG PET/CT have been used to stage and monitor the response to therapy in patients with melanoma. We aim to explore whether local 18F-FDG uptake can predict systemic response and how it correlates with intratumoral infiltration measured by the proportion of “exhausted” antigen experienced T cells (TEx)/Total CD8+ cells. Methods: Following core biopsies or surgical excision, freshly isolated tumor samples were digested and tumor infiltrating lymphocytes (TILs) were extracted and stained with T cell myeloid and activation markers, and analyzed with 14 color FACS. Patients were treated with either Nivolumab 3 mg/kg q2 week or Pembrolizumab 2 mg/kg q3 week. TEx was calculated as % CD8+, PD-1+, CTLA-4+ cells divided by total CD8+ T cells in the tumor sample. Thirty-nine patients (23 males) with measurable advanced melanoma were included. The closest in time, (49 ± 22 days), standard of care whole-body 18F-FDG PET/CT to the biopsy was used for analysis. Uptake was measured by maximum standardized uptake value (SUVmax) at the biopsied lesion. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), for a period of 14±9 months. Results: Of the 18 patients with high TEx (more than 24%), 11 were in CR or PR at follow-up with a SUVmax of 15.8 an, compared to an SUVmax of 10.7 for the 7 patients in PD or SD. Nine of the 21 patients with low TEX (less than 24%) were in PR or CR with an SUVmax of 4.9, significantly lower than the SUVmax of the 12 patients in PD or SD, 10.4. Conclusions: When associated with TEx, local glucose utilization measured by 18F-FDG may be of help for predicting systemic response to check inhibitor mono-therapy. Variations in local increased glucose consumption may reflect several pathophysiologic pathways including different concentrations of activated lymphocyte populations, non-homogenous melanocytic tumoral densities and local inflammatory cellular migrations.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11572
Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.
11572 Background: Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed by 18F-FDG PET/CT have been used to stage and monitor the response to therapy in patients with melanoma. We aim to explore whether local 18F-FDG uptake can predict systemic response and how it correlates with intratumoral infiltration measured by the proportion of “exhausted” antigen experienced T cells (TEx)/Total CD8+ cells. Methods: Following core biopsies or surgical excision, freshly isolated tumor samples were digested and tumor infiltrating lymphocytes (TILs) were extracted and stained with T cell myeloid and activation markers, and analyzed with 14 color FACS. Patients were treated with either Nivolumab 3 mg/kg q2 week or Pembrolizumab 2 mg/kg q3 week. TEx was calculated as % CD8+, PD-1+, CTLA-4+ cells divided by total CD8+ T cells in the tumor sample. Thirty-nine patients (23 males) with measurable advanced melanoma were included. The closest in time, (49 ± 22 days), standard of care whole-body 18F-FDG PET/CT to the biopsy was used for analysis. Uptake was measured by maximum standardized uptake value (SUVmax) at the biopsied lesion. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), for a period of 14±9 months. Results: Of the 18 patients with high TEx (more than 24%), 11 were in CR or PR at follow-up with a SUVmax of 15.8 an, compared to an SUVmax of 10.7 for the 7 patients in PD or SD. Nine of the 21 patients with low TEX (less than 24%) were in PR or CR with an SUVmax of 4.9, significantly lower than the SUVmax of the 12 patients in PD or SD, 10.4. Conclusions: When associated with TEx, local glucose utilization measured by 18F-FDG may be of help for predicting systemic response to check inhibitor mono-therapy. Variations in local increased glucose consumption may reflect several pathophysiologic pathways including different concentrations of activated lymphocyte populations, non-homogenous melanocytic tumoral densities and local inflammatory cellular migrations.
- 3 March 2016
- Vol. 60 (2) , 124-38
Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
Gynecologic malignancies are the leading causes of cancer in women and they represent about 10 to 20% of all solid tumors. During the past few decades, technological advancements in the detection and staging have gained a pivotal role in all oncological processes, including the gynecological ones. Beyond ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging that are conventionally used for anatomical imaging, [18F]FDG imaging and its hybrid further development as PET/CT has become a crucial tool due of its ability to combine functional metabolic and anatomic information, and the ability to image the entire whole body in a single examination. Since the introduction of integrated hybrid PET/CT systems into clinical practice the accurate analysis of the images has detected a number of limitations and pitfalls. The purpose of this review was to describe in detail the different pitfalls related to the use of [18F]FDG PET/CT in the gynecological malignancies, providing imaging examples and discussing possible ways to avoid misinterpretations.
- 3 March 2016
- Vol. 60 (2) , 124-38
Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies.
Gynecologic malignancies are the leading causes of cancer in women and they represent about 10 to 20% of all solid tumors. During the past few decades, technological advancements in the detection and staging have gained a pivotal role in all oncological processes, including the gynecological ones. Beyond ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging that are conventionally used for anatomical imaging, [18F]FDG imaging and its hybrid further development as PET/CT has become a crucial tool due of its ability to combine functional metabolic and anatomic information, and the ability to image the entire whole body in a single examination. Since the introduction of integrated hybrid PET/CT systems into clinical practice the accurate analysis of the images has detected a number of limitations and pitfalls. The purpose of this review was to describe in detail the different pitfalls related to the use of [18F]FDG PET/CT in the gynecological malignancies, providing imaging examples and discussing possible ways to avoid misinterpretations.
- 1 February 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 22 (1) , 221-1
Erratum to: Isolated right ventricular cardiac sarcoidosis demonstrated by 18FDG positron emission tomography
- 1 February 2015
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 22 (1) , 221-1
Erratum to: Isolated right ventricular cardiac sarcoidosis demonstrated by 18FDG positron emission tomography
- 1 July 2014
- Published by Elsevier in PET Clinics
- Vol. 9 (3) , 345-349
PET/MRI Radiotracer Beyond 18F-FDG
- 1 July 2014
- Published by Elsevier in PET Clinics
- Vol. 9 (3) , 345-349
PET/MRI Radiotracer Beyond 18F-FDG